Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

May 5-7, 2016
Zagreb, Croatia

Scientific Agenda

 

Thursday, 5 May 2016

14:00

Welcome and introduction
Srdan Verstovsek, MD, PhD, and Alessandro M. Vannucchi, MD

Session I: Biology of Myeloproliferative Neoplasms and Myelodysplastic Syndromes

Moderator: Mario Cazzola, MD

14:05

Pre-session audience survey

14:15

Lecture: Genetic basis of chronic myelomonocytic leukemia
Eric Solary, MD, PhD

14:35

Lecture: Genetic basis of atypical chronic myeloid leukemia
Carlo Gambacorti-Passerini, MD

14:55

Lecture: Somatic mutations of RNA splicing machinery in MDS
Mario Cazzola, MD

15:15

Break

15:45

Lecture: Cytokines, cells and inflammation in MPN
Marie-Caterine Le Bousse Kerdilès, MD, PhD

16:05

Lecture: Interplay of somatic and germline variants in MPN
Rajko Kusec, MD, PhD

16:25

Panel discussion and post-session audience survey
Mario Cazzola, MD; Marie-Caterine Le Bousse Kerdiles, PhD; Rajko Kusec, MD, PhD; Carlo Gambacorti, MD; Eric Solary, MD, PhD

16:45

Moderator take-home points

16:50

Adjourn

Friday, 6 May 2016

9:30

Welcome to day 2
Srdan Verstovsek, MD, PhD, and Alessandro M. Vannucchi, MD

Session II: Clinical Aspects of Myeloproliferative Neoplasms (I)

Moderator: Jean-Jacques Kiladjian, MD, PhD

9:35

Pre-session audience survey

9:45

Lecture: The WHO updated diagnostic criteria for MPN
Tiziano Barbui, MD

10:05

Lecture: Splanchnic vein thrombosis and MPN: diagnosis and therapy
Valerio De Stafano, MD

10:25

Lecture: Update on long-acting interferons for MPN
Jean-Jacques Kiladjian, MD, PhD

10:45

Break and poster viewing

11:15

Lecture: JAK inhibitors for ET and PV: what have we learned so far
Gunnar Birgegard, MD, PhD

11:35

Lecture: Therapy for “early MF”: pros and cons
Francisco Cervantes, MD, PhD

11:55

Panel discussion and post-session audience survey

12:15

Lunch

Session III: Clinical Aspects of Myelodysplastic Syndromes

Moderator: Martin Jadersten, MD, PhD

14:15

Pre-session audience survey

14:25

Lecture: Mutational profiling in patients with MDS: ready for every-day use in the clinic?
Torsten Haferlach, MD

14:45

Lecture: Quality of life as treatment goal in MDS
Fabio Efficace, PhD

15:05

Break and poster viewing

15:35

Lecture: Erythropoiesis stimulating agents and other growth factors in low-risk MDS: an update
Martin Jadersten, MD, PhD

15:55

Lecture: When HMA fails: Newer therapeutic agents for MDS
Michael Pfeilstöcker, MD, PhD

16:15

Lecture: Novel strategies to prevent relapse after allogeneic transplantation for MDS
Theo De Witte, MD, PhD

16:35

Panel discussion and post-session audience survey

16:55

Moderator take-home points

17:00

Adjorn

Saturday, 7 May 2016

9:00

Welcome to day 3
Srdan Verstovsek, MD, PhD, and Alessandro M. Vannucchi, MD

Session IV: Clinical Aspects of Myeloproliferative Neoplasms (II)

Moderator: Mary F. McMullin, MD, FRCP, FRCPath

9:05

Pre-session audience survey

9:15

Lecture: Mutation-based risk stratification approaches in MF: any real clinical utility?
Presenter: Paola Guglielmelli, MD, PhD

9:35

Lecture: Update on JAK inhibitors for myelofibrosis: there is more than one
Presenter: Srdan Verstovsek, MD, PhD

9:55

Lecture: How to manage side effects of JAK inhibitors for MF in the clinical practice
Presenter: Mary F. McMullin, MD, FRCP, FRCPath

10:15

Break

10:45

Lecture: Influence of mutational status on timing, outcome and post-transplant management of MF patients
Presenter: Nicolaus Kröger, MD

11:05

Lecture: Novel agents and combination therapies in MF
Presenter: Alessandro M. Vannucchi, MD

11:25

Panel discussion and post-session audience survey
Paola Guglielmelli, MD, PhD; Srdan Verstovsek, MD, PhD; Mary Frances McMullin, MD, FRCP, FRCPath; Nicolas Kröger, MD, PhD; Alessandro M. Vannucci, MD

11:45

Adjourn